%0 Journal Article %A Jodie D. Ouahed %A Achille Broggi %A Abigail Glick %A Robin T. Haring %A Michael Field %A Daniel Chinnapen %A Michael J. Grey %A Wayne Lencer %A Steven J. Steiner %A Evida Dennis-Heyward %A Noah Shroyer %A Zachary Criss %A Shih-Ching Lin %A Xi-Lei Zeng %A Sue E. Crawford %A Mary K. Estes %A Jay R. Thiagarajah %A Amalia Capilla %A Whitney Scoon %A Gustavo Mostoslavsky %A Jason Spence %A Christoph Klein %A Aleixo M. Muise %A Bruce Horwitz %A Ivan Zanoni %A Scott B. Snapper %T Variants in Interferon Lambda are Associated with Very Early Onset Inflammatory Bowel Disease %D 2022 %R 10.1101/2022.03.17.22271929 %J medRxiv %P 2022.03.17.22271929 %X Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of the intestine that affect children and adults. The etiology is multifactorial with the contribution of genetic, immune, microbial, and environmental risk factors with a substantial involvement of host:microbial cross-talk in the lumen. Whether and how antiviral responses contribute to IBD pathogenesis is under intense investigation. Here, we identified two unrelated patients diagnosed with very early onset IBD (VEOIBD) with rare variants in type III Interferons (IFNs), also known as interferon lambdas (IFNλs), a group of IFNs that play key roles in the protection against enteric viruses. The first patient was found to have homozygous variants in both IFNL2 and IFNL3, the genes encoding, IFN-λ2 and IFN-λ3, respectively. The second patient was found to have inherited compound heterozygous variants in IFNL3, with one of the two alleles bearing the same variant as the first patient. Functional analyses revealed that the proteins coded for by these variant IFN-λ genes exhibited defects in the induction of IFN signaling. More detailed assessment of the variants identified in Patient 1 demonstrated defects in their ability to bind to IFN-λ receptor 1 (IFNLR1), as well as their ability to induce heterodimerization of IFNLR1 and IL10RB, which together compromise the functional receptor for IFN-λ (IFNLR). These patient-encoded IFN-λ variants also exhibit defects in the ability to induce robust downstream IFN-stimulated genes (ISGs) in patient-derived intestinal organoids. All in all, we demonstrate that VEOIBD is associated with variants in IFN-λs and defective induction of downstream IFN signaling.Competing Interest StatementJ.D.O. declares the following interest: independent contractor as Speaker for Janssen and consultant for Skygenics. SBS declares the following interests: Scientific advisory board participation for Pfizer, BMS, Lilly, IFM therapeutics, Merck, and Pandion Inc; Grant support from Pfizer, Novartis, Amgen, and Takeda; Consulting for Hoffman La Roche, Takeda, and Amgen.Funding StatementSBS is supported by NIH grant P30DK03485, RC2DK122532, R01DK115217, the Wolpow Family Chair in IBD Treatment and Research, the Translational Investigator Service at Boston Children ′s Hospital, and the Children ′s Rare Disease Cohort (CRDC) Study. IZ is supported by NIH grant 1R01AI121066, 1R01DK115217, 1R01AI165505 and contract no. 75N93019C00044, Lloyd J. Old STAR Program CRI3888, and holds an Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund. AB is supported by: the excellence initiative of Aix Marseille Universit é –A*Midex, a French ″ investissements d ′Avenir ″ program: AMX-20-CE-01; the FRM amor çage de jeunes equipes grant AJE202010012468 and the ANR-JCJC grant ″INTERMICI ″ ANR-21-CE15-0022. JO is supported by NIH grant K08 DK122133-01A1, the Boston Children ′s Hospital Translational Research Program Mentored Translational Investigator Service Award. RTH is supported by the AGEM International Student Research Fellowship Grant Next generation sequencing was supported by Merck Research Labs. X-LZ, S-CL, SEC and MKE are supported by NIH grants DK P30DK056338, P01 AI 057788 and R01 AI 080656.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB protocol P00027983 of Boston Children's Hospital approved this work and we have consent to publish this information.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors %U https://www.medrxiv.org/content/medrxiv/early/2022/03/20/2022.03.17.22271929.full.pdf